Open Access

ARTICLE

RCN3 Expression Indicates Prognosis in Colorectal Cancers

by Shengzhe Ma^1,#, Xiaoming Zhu^1,#, Cheng Xin^1,#, Fuao Cao¹, Mengnan Xu¹, Xiangling Han¹, Jinke Sui^3,*, Wenjun Chang^2,*, Wei Zhang^1,*

1 Department of Colorectal Surgery, Changhai Hospital, Shanghai, 200433, China
2 Department of Environmental Health, Naval Medical University, Shanghai, 200433, China
3 Jiahui International Cancer Center, Jiahui International Hospital, Shanghai, 200433, China

* Corresponding Authors: Jinke Sui. Email: ; Wenjun Chang. Email: ; Wei Zhang. Email:
# Contributed equally to this work

Oncologie 2022, 24(4), 823-833. https://doi.org/10.32604/oncologie.2022.025411

Received 10 July 2022; Accepted 22 September 2022; Issue published 31 December 2022

Abstract

Background: Reticulocalbin 3 (RCN3) has been associated with several malignancies. However, its role in colorectal cancer (CRC) remains controversial. Thus, this study aimed to investigate the role of RCN3 in CRC prognosis. Methods: The clinical significance of RCN3 expression in CRC was evaluated in a large cohort of 483 patients. Normal tissues, carcinoma, para-carcinoma, adenoma, and metastatic tissues were evaluated by immunohistochemistry. We investigated the association between RCN3 expression and CRC occurrence in tumors and other tissues. Prognostic factors were also evaluated by Kaplan-Meier survival analysis and the Cox regression model. Results: RCN3 was significantly overexpressed in CRC and metastatic tissues. Patients with high RCN3 expression had shorter disease-free survival than those with low RCN3 expression. Multivariate Cox regression analysis showed a risk ratio HR], 0.607; confidence interval [CI], 0.362–1.016; p < 0.05 after adjusting for other prognostic factors. HighRCN3 expression was also associated with a worse chemotherapeutic response in the colon (p < 0.01) or rectal (p < 0.05) cancer patients who received adjuvant chemotherapy. Conclusion: RCN3 expression level is an independent risk factor and serves as a prognostic biomarker for CRC. High RCN3 expression predicts poor prognosis and chemotherapeutic response.

---

Keywords

---